Paper Details

  1. Home
  2. Paper Details

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.

Author: FosaasK, HendsetM, HermannM, HjerpsetM, RefsumH

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluates venlafaxine pharmacokinetics in patients with heterozygous extensive metaboliser (HEM) status for the CYP2D6 enzyme. This is important as patients with defective CYP2D6 function have increased systemic exposure and side effects with venlafaxine.
Paper Details　
Original Abstract of the Article :
Increased systemic exposure of the antidepressant venlafaxine and increased risk of side effects has previously been observed in patients with defective CYP2D6 function [poor metabolisers (PMs)]. The aim of this study was to evaluate venlafaxine pharmacokinetics in carriers of one functional and one...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00228-007-0453-7

データ提供：米国国立医学図書館（NLM）

Understanding Venlafaxine Pharmacokinetics in CYP2D6 Allele Carriers

Venlafaxine, an antidepressant, is metabolized by the enzyme CYP2D6. Variations in CYP2D6 activity can influence drug metabolism and potentially affect treatment outcomes. This study investigates the pharmacokinetics of venlafaxine and its metabolites in individuals carrying one functional and one defective CYP2D6 allele, known as heterozygous extensive metabolizers (HEMs). The authors explored the potential impact of CYP2D6 genotype on venlafaxine metabolism and the implications for treatment.

Tailoring Venlafaxine Treatment for Genetic Variations

The study's findings highlight the importance of considering genetic variations in CYP2D6 activity when prescribing venlafaxine. The results emphasize the need for personalized treatment approaches, adjusting dosages and monitoring for side effects based on individual genotype. This study encourages further research to optimize venlafaxine therapy for patients with different CYP2D6 genotypes.

A Personalized Approach to Antidepressant Treatment

This study, like a skilled pharmacist carefully compounding medications, underscores the importance of personalized medicine in antidepressant treatment. The findings highlight the need to consider individual genetic variations in CYP2D6 activity when prescribing venlafaxine. This study encourages us to embrace a more tailored approach to medication management, maximizing therapeutic benefits and minimizing potential side effects.

Dr.Camel's Conclusion

This study delves into the intricate world of venlafaxine metabolism, revealing the influence of CYP2D6 genotype on drug pharmacokinetics. The findings encourage a personalized approach to antidepressant treatment, ensuring optimal outcomes and minimizing potential adverse effects.

Date :
  1. Date Completed 2008-07-31
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

18214456

DOI: Digital Object Identifier

10.1007/s00228-007-0453-7

Related Literature

Article Analysis
・Side Effects of desvenlafaxine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.